Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Is Cara Therapeutics a Buy?

By Maxx Chatsko - Updated Apr 22, 2019 at 2:14PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The $600 million pharma company is working on a drug with estimated peak annual sales of $500 million.

The morbid reality of the opioid epidemic is all around us. About 30,000 people die in the U.S. each year from overdoses involving opioids; that's 82 people a day, according to the Centers for Disease Control.

The crisis has pushed drug makers to search for abuse-tolerant pain treatments. These are often drugs that selectively target specific opioid receptors in the central nervous system that aren't likely to cause dependence, which is an all too common side effect of opioids like morphine, oxycodone, and hydrocodone that primarily target the mu-opioid receptor, known as the gateway to addiction.

A hand placing blocks with medical icons on them in a triangular tower.

Image source: Getty Images.

Cara Therapeutics ( CARA 2.22% ) is developing a single asset belonging to a novel class of drugs called kappa opioid receptor agonists. In addition to bearing the "abuse-tolerant" label, the drug candidate has avoided other common side effects associated with traditional opioids, such as nausea, sedation, and respiratory depression. The little pharma company has impressed Wall Street in recent years but still trades at a market cap of only $600 million. Should opportunistic investors consider the stock a buy?

The therapeutic approach

Cara Therapeutics is developing its CR845 drug in five different indications. However, each clinical trial is evaluating the drug candidate's potential to selectively target kappa-opioid receptors as a way to treat either pain or pruritus, a technical term for itching.

Investors are most excited about the drug candidate's potential in chronic kidney disease-associated pruritus (CKD-aP), a severe form of itching some dialysis patients suffer from. It may seem like a niche area, but an estimated 270,000 Americans suffer from the condition. Analysts think the drug candidate, branded as Korsuva in this indication, could generate over $500 million per year in peak sales.

The market opportunity, coupled with solid midstage trial results, allowed Cara Therapeutics to de-risk the drug candidate's development and potential commercialization by inking a deal in May 2018 with Vifor Fresenius Medical Care Renal Pharma (VFMCRP), a joint venture between Vifor Pharma Group and the largest dialysis provider in the U.S. Fresenius Medical Care. In other words, it's a great partner for Korsuva.

Cara Therapeutics collected $70 million in upfront payments from this endeavor. It also stands to receive royalties on all sales and up to $470 million in additional milestone payments. And that's just for an injectable formulation of Korsuva. The small-cap company owns the rights to all other uses of CR845. That includes an oral formulation of Korsuva for CKD-aP and chronic liver disease-associated pruritus, in addition to intravenous and oral formulations of CR845 for post-operative pain and chronic pain, respectively.  

By the numbers

As a development-stage company with all its value wrapped up in its lone pipeline asset, Cara doesn't have much to report in terms of revenue or income. However, investors can consider the company's cash position and cash burn.

The $600 million company finished September 2018 with $206 million in cash, cash equivalents, and marketable securities. That was bolstered by $92 million in net proceeds from a stock offering in July 2018.

Regarding cash burn, the company generated $2 million in operating cash flow in the first nine months of 2018, but only after accounting for deferred revenue related to performance obligations from the agreement with VFMCRP. In other words, the company believes it's due some portion of the $470 million in milestone payments very soon, so it's accounting for that as deferred revenue, which is reported as a liability and so it's factored out of the operating cash flow figure.  

Cash is cash no matter how it's generated. While investors are surely pleased that Cara Therapeutics has de-risked the development of Korsuva and its overall pipeline, perhaps it's more telling to look at operating losses. In the first nine months of 2018, the business lost $53 million from operations, a greater loss than the $44 million loss in the same period last year. Considering its strong cash position and potential to receive additional milestone payments in the near future, the balance sheet is not likely to be a source of risk. 

An arrow bouncing up shelves on the wall.

Image source: Getty Images.

Should you add Cara Therapeutics stock to your portfolio?

After hitting some turbulence in December, Cara Therapeutics gained just 6% in 2018 but then recovered some ground in January. The promising pharma company trades at a market cap of just $600 million.

If the development of Korsuva and CR845 proves successful, the company will become worth more than its current valuation. But because it's entirely dependent on a single asset, failure in the clinic would make the company worth far less than its current valuation. This is the ultimate binary stock dilemma; it could really go either way and we just don't know yet.

The upside is attractive at a market cap of only $600 million, especially considering Korsuva would hit the ground running with immediate access to roughly 38% of U.S. dialysis treatment centers if it earns marketing approval. Investors aware of the risk might not lose sleep over opening a small position in the business right now. Why not have a little fun with a potential multibagger?

Check out the latest Cara Therapeutics earnings call transcript.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Cara Therapeutics, Inc. Stock Quote
Cara Therapeutics, Inc.
CARA
$12.89 (2.22%) $0.28

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
634%
 
S&P 500 Returns
141%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/02/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.